The current research paradigm for Huntington's disease is based on participants with overt
clinical phenotypes and does not address its pathophysiology nor the biomarker changes …

Huntington's disease is an autosomal dominant, progressive neurodegenerative disorder,
for which there is no disease-modifying treatment. By use of predictive genetic testing, it is …

Huntington's disease is a progressive, fatal, neurodegenerative disorder caused by an
expanded CAG repeat in the huntingtin gene, which encodes an abnormally long …

Background Huntington's disease (HD) is an autosomal dominant, fully penetrant,
neurodegenerative disease that most commonly affects adults in mid-life. Our aim was to …

Background Disease-modifying treatments are in development for Huntington's disease;
crucial to their success is to identify a timepoint in a patient's life when there is a measurable …

Background TRACK-HD is a multinational prospective observational study of Huntington's
disease (HD) that examines clinical and biological findings of disease progression in …

Established in July 2012, Enroll-HD is both an integrated clinical research platform and a
worldwide observational study designed to meet the clinical research requirements …

Background TRACK-HD is a prospective observational biomarker study in premanifest and
early Huntington's disease (HD). In this report we define a battery of potential outcome …

Background Although the association between cytosine-adenine-guanine (CAG) repeat
length and age at onset of Huntington's disease is well known, improved prediction of onset …

Background TRACK-HD is a prospective observational study of Huntington's disease (HD)
that examines disease progression in premanifest individuals carrying the mutant HTT gene …